ES2755933T3 - Tratamiento contra el cáncer usando un antagonista del receptor del factor de crecimiento insulínico (IGF) en combinación con exemestano y everolimus - Google Patents

Tratamiento contra el cáncer usando un antagonista del receptor del factor de crecimiento insulínico (IGF) en combinación con exemestano y everolimus Download PDF

Info

Publication number
ES2755933T3
ES2755933T3 ES15703743T ES15703743T ES2755933T3 ES 2755933 T3 ES2755933 T3 ES 2755933T3 ES 15703743 T ES15703743 T ES 15703743T ES 15703743 T ES15703743 T ES 15703743T ES 2755933 T3 ES2755933 T3 ES 2755933T3
Authority
ES
Spain
Prior art keywords
seq
antibody
light chain
heavy chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15703743T
Other languages
English (en)
Spanish (es)
Inventor
Thomas Bogenrieder
Ulrike Weyer-Czernilofsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Application granted granted Critical
Publication of ES2755933T3 publication Critical patent/ES2755933T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
ES15703743T 2014-01-24 2015-01-23 Tratamiento contra el cáncer usando un antagonista del receptor del factor de crecimiento insulínico (IGF) en combinación con exemestano y everolimus Active ES2755933T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14152416 2014-01-24
PCT/EP2015/051308 WO2015110560A1 (en) 2014-01-24 2015-01-23 Cancer treatment using an insulin-like growth factor (igf) receptor antagonist in combination with exemestane and everolimus

Publications (1)

Publication Number Publication Date
ES2755933T3 true ES2755933T3 (es) 2020-04-24

Family

ID=49999770

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15703743T Active ES2755933T3 (es) 2014-01-24 2015-01-23 Tratamiento contra el cáncer usando un antagonista del receptor del factor de crecimiento insulínico (IGF) en combinación con exemestano y everolimus

Country Status (14)

Country Link
US (1) US20150209426A1 (https=)
EP (1) EP3096792B1 (https=)
JP (1) JP6712226B2 (https=)
CY (1) CY1122432T1 (https=)
DK (1) DK3096792T3 (https=)
ES (1) ES2755933T3 (https=)
HR (1) HRP20192260T1 (https=)
HU (1) HUE047614T2 (https=)
LT (1) LT3096792T (https=)
PL (1) PL3096792T3 (https=)
PT (1) PT3096792T (https=)
RS (1) RS59649B1 (https=)
SI (1) SI3096792T1 (https=)
WO (1) WO2015110560A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ592151A (en) 2008-12-12 2012-10-26 Boehringer Ingelheim Int Anti-igf antibodies
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
US20200239559A1 (en) * 2017-09-29 2020-07-30 Boehringer Ingelheim International Gmbh Anti igf, anti pd-1, anti-cancer combination therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20090368A1 (es) * 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
NZ592151A (en) * 2008-12-12 2012-10-26 Boehringer Ingelheim Int Anti-igf antibodies
WO2013169611A1 (en) * 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Compositions and methods for treating breast cancer

Also Published As

Publication number Publication date
JP2017505311A (ja) 2017-02-16
EP3096792B1 (en) 2019-09-25
SI3096792T1 (sl) 2020-01-31
LT3096792T (lt) 2019-12-27
WO2015110560A1 (en) 2015-07-30
HRP20192260T1 (hr) 2020-03-06
RS59649B1 (sr) 2020-01-31
PT3096792T (pt) 2020-01-08
JP6712226B2 (ja) 2020-06-17
US20150209426A1 (en) 2015-07-30
CY1122432T1 (el) 2021-01-27
HUE047614T2 (hu) 2020-04-28
DK3096792T3 (da) 2019-12-09
PL3096792T3 (pl) 2020-05-18
EP3096792A1 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
Arteaga et al. Treatment of HER2-positive breast cancer: current status and future perspectives
AU2014224608B2 (en) Combination therapy for neoplasia treatment
JP5981853B2 (ja) ニューレグリンアンタゴニスト及び癌の治療におけるそれらの使用
Ahmad Introduction to cancer metastasis
JP2019515916A (ja) グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法
TW202220654A (zh) 用於治療癌症之組合
JP2023502585A (ja) 癌の治療のための、ＰＤ－１、ＴＧＦβ、及びＴＩＧＩＴの組み合わせ阻害
CN103890007A (zh) 神经调节蛋白抗体及其用途
Singh et al. A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models
ES2755933T3 (es) Tratamiento contra el cáncer usando un antagonista del receptor del factor de crecimiento insulínico (IGF) en combinación con exemestano y everolimus
CA2757730A1 (en) Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors
CN102227635A (zh) Na/K-ATP酶表达作为癌症治疗的指示剂
US20210198350A1 (en) Use of a sclerostin antagonist
ES3030540T3 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
JP2022514087A (ja) ＩＬ－１β結合抗体の使用
ES2777501T3 (es) Terapia de anticuerpos ANTI-VEGFR2 para carcinoma hepatocelular
US20150037336A1 (en) Combination of hb-egf binding protein and egfr inhibitor
US20170196888A1 (en) Compositions and methods for treating cancer
HK40109234A (zh) 用於治疗癌症的方法和组合物
Jyoti et al. Role of Systemic Therapy in the Management of Uterine Sarcomas
Searle et al. 104th Annual Meeting of the American Association for Cancer Research (AACR), Washington, DC, USA-March 6-10, 2013
Shabaya et al. Novel therapeutic strategies and combinations for HER2-overexpressing breast cancer
US20130259929A1 (en) Use of a phosphopeptide able to block her3/p85 interaction for the treatment of her2 hyper-expressing tumours
TW201532613A (zh) 用於贅瘤（ｎｅｏｐｌａｓｉａ）治療之組合療法